ArticleFrontiers in pharmacology2026
An analysis of the burden of drug use disorders from 1990 to 2023: differences between China, India, and the United States.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug use disorders (DUDs) represent a significant global health burden with marked regional variations. This study compares DUDs burden, trends, and projections among China, India, and the United States (US)-three countries comprising approximately 40% of the world's population and spanning a socio-demographic index (SDI) range from 0.61 to 0.88-to elucidate how developmental stages influence DUDs patterns and inform targeted interventions. Methods: Data on the incidence, prevalence, deaths, and disability-adjusted life years (DALYs) of DUDs from 1990 to 2023 were extracted from the Global Burden of Disease Study 2023, stratified by sex, age group, and drug subtype. Temporal trends were analyzed via Joinpoint regression, and future burden to 2040 was projected using the Nordpred age-period-cohort model. Results: In 2023, the US had the highest age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR), while India had the lowest. From 1990 to 2023, China showed declining trends across all age-standardized rate (ASR), in contrast to rising trends in the US; India showed mixed trends, with rises in ASIR, ASPR, and ASDR but a slight decrease in ASMR. The burden was concentrated in younger adults and men. Opioid use disorders contributed most to deaths and DALYs in all three countries. Projections from 2024 to 2040 indicate marked divergence: the US is expected to see growth across all indicators, with deaths nearly doubling (109.59%) and ASMR increasing by 90.76%; India is projected to experience rises in ASMR (30.40%) and ASDR (15.73%); while China shows modest increases across all ASR (4.61%-24.23%) despite a decline in incident cases (-7.45%). Conclusion: DUDs burden and trends differ markedly among the three countries. Emerging trends underscore the need for sustained, targeted interventions focusing on high-risk populations and specific drug types to mitigate future impacts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.